The latter includes (1) exposure to medications, such as valproic acid (VPA) and selective serotonin reuptake inhibitors (SSRIs) (2), maternal complications during pregnancy, including infection and hypertensive disorders of pregnancy, and (3) high parental age
Description Research Only Use: This material is sold strictly for in vitro laboratory research use only
Also at week 26, significantly greater reductions in body weight were reported with both combination regimens 1.8 kg for ertu 5 mg/sita 100 mg, and 2.3 kg for ertu 15 mg/sita 100 mg, beyond sita 100 mg alone, where the reduction was 0.7 kg (both p 0.001)
Important: Powered by a science-backed blend of ingredients shown to support GLP-1 activity, promote appetite control, aid weight management, and nourish overall gut wellness
Most users report minimal side effects